Key Points
- CFO Kory James Wentworth sold 2,500 shares on April 1 at an average price of $12.95 under a pre-arranged Rule 10b5-1 plan, trimming his stake by 2.06% to 119,010 shares (worth about $1.54M).
- The April sale follows several sizable March dispositions (11,388 shares on Mar 10 at $13.02; 5,089 on Mar 9 at $13.00; 7,988 on Mar 4 at $12.25), signaling notable insider selling over recent weeks.
- Entrada (TRDA) trades near its 1-year high (~$13.66) with a market cap of ~$503M; the company recently beat EPS estimates but missed revenue, and analysts hold a mixed view with a consensus "Moderate Buy" and an average target of $18.50.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 2,500 shares of Entrada Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total value of $32,375.00. Following the completion of the sale, the chief financial officer owned 119,010 shares of the company's stock, valued at $1,541,179.50. This trade represents a 2.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kory James Wentworth also recently made the following trade(s):
- On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.02, for a total transaction of $148,271.76.
- On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.00, for a total transaction of $66,157.00.
- On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total transaction of $97,853.00.
Entrada Therapeutics Stock Performance
Shares of TRDA stock opened at $13.15 on Friday. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $13.66. The company has a 50 day moving average price of $11.76 and a 200 day moving average price of $9.60. The firm has a market capitalization of $503.38 million, a price-to-earnings ratio of -3.80 and a beta of -0.15.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. As a group, equities analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have weighed in on TRDA. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Wall Street Zen cut shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Oppenheimer began coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an "outperform" rating and a $21.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Entrada Therapeutics in a research report on Wednesday. They issued an "overweight" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Entrada Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $18.50.
Check Out Our Latest Stock Report on TRDA
Hedge Funds Weigh In On Entrada Therapeutics
A number of institutional investors have recently made changes to their positions in TRDA. State of Wyoming boosted its stake in shares of Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company's stock valued at $51,000 after buying an additional 4,295 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after buying an additional 3,707 shares during the last quarter. AXQ Capital LP acquired a new stake in Entrada Therapeutics in the third quarter valued at $67,000. Occudo Quantitative Strategies LP bought a new position in Entrada Therapeutics during the 2nd quarter valued at $68,000. Finally, Inscription Capital LLC bought a new position in Entrada Therapeutics during the 3rd quarter valued at $69,000. 86.39% of the stock is owned by institutional investors and hedge funds.
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
